| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9336486 | Brachytherapy | 2005 | 11 Pages |
Abstract
The results failed to show any superiority of prostatectomy over brachytherapy with 103Pd (TheraSeed; Theragenics Corp., Buford, GA) regarding time until relapse as indicated by PSA level increase (>0.4 ng/mL for prostatectomy and >3 successive rises in PSA as defined by ASTRO). We recently reviewed our techniques and improved equipment from 1995 to present and found major gains with both brachytherapy and surgery. Low risk brachytherapy resulted in 99% freedom from PSA failure while surgery showed results of 97%. Brachytherapy and prostatectomy should be offered without bias to all men with stage T1 and T2 organ-confined prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jerrold Sharkey, Alan Cantor, Zucel Solc, William Huff, Stanley D. Chovnick, Raymond J. Behar, Ramon Perez, Juan Otheguy, Richard Rabinowitz,